Abstract
Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.
©2019 American Association for Cancer Research.
MeSH terms
-
Anilides / administration & dosage
-
Anilides / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Carcinoma, Hepatocellular / mortality
-
Carcinoma, Hepatocellular / pathology
-
Carcinoma, Hepatocellular / therapy*
-
Chemoembolization, Therapeutic
-
Clinical Trials as Topic
-
Humans
-
Immunotherapy / methods
-
Liver Neoplasms / mortality
-
Liver Neoplasms / pathology
-
Liver Neoplasms / therapy*
-
Molecular Targeted Therapy / methods
-
Mutation
-
Phenylurea Compounds / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use
-
Pyridines / administration & dosage
-
Pyridines / therapeutic use
-
Quinolines / therapeutic use
-
beta Catenin / genetics
Substances
-
Anilides
-
Antibodies, Monoclonal, Humanized
-
CTNNB1 protein, human
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Pyridines
-
Quinolines
-
beta Catenin
-
cabozantinib
-
atezolizumab
-
lenvatinib